In a nutshell This study compared the long-term outcomes of umbilical cord (UC) blood transplantation versus unrelated donor transplantation (UD) in patients with acute myeloid leukemia (AML). The data showed that long-term outcomes for patients in complete remission two years after transplantation was not impacted by donor...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including chronic lymphocytic leukemia (CLL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....
Read More
In a nutshell This study evaluated the effectiveness and safety of idelalisib (Zydelig) combined with rituximab (Rituxan) in the treatment of patients with chronic lymphocytic leukemia (CLL) in a real-world setting. The data supported the effectiveness of this regimen in routine practice for these patients. Some background Idelalisib (IDL) is an...
Read More
In a nutshell This study investigated the clinical benefits and safety of FMS-like tyrosine kinase 3 inhibitors (FLT3i) in various treatment stages of acute myeloid leukemia (AML). The data showed that FLT3is safely improved prognosis in the induction stage (first-line treatment) of newly diagnosed FLT3-positive AML and salvage therapy (treatment...
Read More
In a nutshell This study explored the factors that affect fatigue severity and the relationship between fatigue severity and health-related quality of life (HRQoL) among patients with chronic myeloid leukemia (CML). The data showed that worse fatigue was associated with high body mass index (BMI; weight in relation to height) and more sleep...
Read More
In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Some background The number of treatment options for CLL and SLL has increased in the last few years....
Read More
In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Some background The number of treatment options for CLL and SLL has increased in the last few years....
Read More
In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...
Read More
In a nutshell The study aimed to investigate the ability of dasatinib (Sprycel) to penetrate the brain in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) at risk for central nervous system (CNS; brain and spinal cord) relapse. This study concluded that a dose of 140mg per day...
Read More
In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL). This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...
Read More
In a nutshell The study aimed to investigate the health-related quality of life (HR-QoL) for patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (VEN; Venclexta) and obinutuzumab (Obi; Gazyva). This study concluded that this treatment is effective and does not impair the quality of life in these...
Read More
In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...
Read More
